Incretins: what does the future hold?
Edelman
Steven V
SV
University of California San Diego School of Medicine, San Diego, California 92161, USA. sedelman@ucsd.edu
D000218:Adamantane / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism*; D001835:Body Weight; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism*; D018819:Dipeptidyl Peptidase 4 / Q000378:metabolism; D000077270:Exenatide; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D000069450:Liraglutide; D009570:Nitriles; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D011759:Pyrrolidines; D014688:Venoms / Q000494:pharmacology / Q000627:therapeutic use; D000077597:Vildagliptin
D001786:Blood Glucose; D009570:Nitriles; D010455:Peptides; D011480:Protease Inhibitors; D011759:Pyrrolidines; D014688:Venoms; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide; D018819:Dipeptidyl Peptidase 4; D000077597:Vildagliptin; D000218:Adamantane